Nigel Blackburn

Director of Drug Development, Centre for Drug Development

Cancer Research UK

Nigel joined Cancer Research UK in May 2009, having previously worked in a variety of senior management roles in the pharma and biotech sectors.

Nigel Blackburn

Nigel is responsible for Cancer Research UK’s early drug development activity, translating novel agent scientific programmes through to clinic.

Currently, Nigel and his team at the CR-UK Centre for Drug Development manage a diverse portfolio of ~25 novel agents at various stages of development from GMP production, regulatory preclinical studies, through to first-in-human, phase I and early phase II clinical trials.